Business Wire

Ferring Pharmaceuticals and North Zealand University Hospital Announce eHealth Collaboration Aimed at Transforming IBD Patient Care

Del

To mark World IBD Day 2016, Ferring Pharmaceuticals and North Zealand University Hospital in Copenhagen today announced a multi-year collaboration aimed at transforming the way in which patients with inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) manage their condition and receive medical care.

The new programme, fully funded by Ferring Pharmaceuticals and governed by North Zealand University Hospital, is based on an innovative eHealth platform that empowers patients to self-monitor and self-treat by enabling them to screen for disease activity, act proactively on their symptoms and increase adherence to therapy.

“In my clinical practice, IBD patients who are monitored by an e-health programme have a reduced time-to-remission,” said Professor Pia Munkholm. “This effect is linked to the patient’s ability to more tightly monitor their condition on the web than in a standard care setting, giving users of the eHealth programme the opportunity to detect a relapse sooner.”

During the partnership, North Zealand University Hospital will also work to evaluate the role of the microbiome in patient responses to different treatments in an eHealth setting. North Zealand University Hospital has a deep understanding of the human microbiome and Ferring Pharmaceuticals, as a leader in the area of gastroenterology, shares a mutual interest in expanding research in this area.

“Ferring and North Zealand University Hospital both fully embrace the concept of eHealth and its positive effects in relation to patient empowerment,” said Per Falk, MD, PhD, Executive Vice President and Chief Scientific Officer at Ferring. “This partnership will assure continued focus on eHealth and generate personalised treatment for IBD patients.”

- Ends -

About Inflammatory bowel disease (IBD):

Inflammatory bowel disease (IBD) is a chronic relapsing idiopathic inflammation of the gastrointestinal tract (GIT). The two most common forms of IBD are Crohn’s disease and Ulcerative colitis which together affect over 3.6 million persons worldwide. IBD is characterized by an aberrant mucosal immune response observed locally in GIT leading to impaired epithelial barrier function and tissue destruction. A combination of factors such as immune response, gut bacteria, environmental triggers and genes are all thought to contribute to the disease – and a treatment plan that includes both regular medical treatment and the right diet is therefore important to allow the patient to manage symptoms and live a normal life. Over the past decade IBD have emerged as one of the most studied human conditions linked to the gut microbiota.

About Irritable bowel syndrome (IBS):

Irritable bowel syndrome (IBS) on the other hand has no organic course, however, is has been linked to dysbiosis of the gut microbiota in many studies. IBS is the most common GI disorder affecting 10-15% in the industrialized world. Abdominal pain and altered bowel habits are the most bothersome symptoms for many IBS patients which greatly affect their quality of life. Treatment of IBS patients rely so far on symptom reduction. Many IBS patients has reported their symptoms to be triggered by meals or specific food - foods are also one of the most important environmental factors impacting the microbial composition in the gut.

About eHealth

eHealth (also known as Telemedicine) is relatively recent term for healthcare practice that can encompass the use of telecommunication and information technologies to provide physical and psychological diagnosis and treatments at a distance, including telemonitoring of patients functions.

About Microbiota:

The microbiota can be considered a “new organ” which actually constitutes 2 kg of our body and an estimated 80 % of its components has not yet been cultivated.

About Ferring Pharmaceuticals:

Headquartered in Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of reproductive health, urology, gastroenterology, endocrinology and orthopaedics. Ferring has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries. To learn more about Ferring or its products please visit www.ferring.com.

Contact information

Ferring Pharmaceuticals
Helen Gallagher, +41 58 301 00 51
helen.gallagher@ferring.com
or
Nicole Barraud-Estoppey, +41 58 301 00 53
nicole.barraud-estoppey@ferring.com
or
North Zealand University Hospital
Pia Munkholm, +4540858494
Professor
pia_munkholm@mail.dk

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Department for International Trade: Life Sciences at the Heart of UK Economy18.7.2018 12:38Pressemelding

The Government will today (Wednesday 18 July) host the second in a series of roundtables with stakeholders from key life science businesses, demonstrating the importance of the sector to the UK economy. The Chancellor, International Trade Secretary, Business Secretary and Health and Social Care Secretary will be amongst those that meet with senior representatives from leading UK and international life sciences companies as the UK positions itself as the global home of health innovation, welcoming overseas investment and seeking to boost exports in the process. Discussions at the roundtable will focus on how the future of the Life Sciences sector will be supported by the delivery of our modern Industrial Strategy, ensuring that the UK is ‘open for business’ with a positive business environment, our ambitions for a comprehensive agreement with the EU on our future relationship and the development and implementation of our independent trade policy. To date, the government has engaged sign

Universal Laser Systems Expands Its Materials Database with 3M, Victrex and Dexmet Materials18.7.2018 12:05Pressemelding

Universal Laser Systems (ULS) announces the addition of 3M™, Victrex® and Dexmet materials to its materials database, the most extensive repository of laser material processing parameters for materials in the range of 10 watts to 500 watts. The 3M, Victrex and Dexmet materials new to the ULS materials database were specifically added for laser processing with the ULTRA and XLS platforms, suited for high accuracy and precision laser cutting, laser ablation and laser surface modification. The materials include: 3M™ Extreme Sealing Tape 4412N 3M™ Thermally Conductive Silicone Interface Pad 5516 Victrex® APTIV® PEEK Film Dexmet PolyGrid® 8PTFE10-125ST Expanded PTFE Dexmet MicroGrid® AL 25 Expanded Aluminum Laser processing notes, describing the results of the laser-material interaction for these materials, are also available in the Materials Library on the ULS website to help potential customers explore the advantages of deploying laser technology within their manufacturing, research and d

Sterigenics Expands European Capacity With New State-of-the-Art Gamma Sterilization Facility in the UK18.7.2018 12:00Pressemelding

Sterigenics, a Sotera Health company and leading global provider of mission-critical sterilization solutions and expert advisory services, announced today it is building a new facility in Markham Vale North in Chesterfield/Derbyshire, UK. The facility will significantly expand Sterigenics’ footprint in Europe to help meet the growing sterilization needs of its customers and support the company’s mission of Safeguarding Global HealthTM. Scheduled for completion in the fourth quarter, 2018, the facility will include the installation of a state-of-the-art Nordion JS10000 gamma irradiator with a research loop. The new 60,000-square-foot facility will add gamma sterilization capabilities in the UK to complement Sterigenics’ existing ethylene oxide (EtO) facility based in Somercotes/Derbyshire. “Sterigenics is committed to being the world’s leading provider of sterilization services and partnering with our customers to eliminate threats to human health,” said Philip Macnabb, President of Ste

Smiths Detection Technology Chosen for Standard 3 Upgrade at Helsinki Airport18.7.2018 09:05Pressemelding

Smiths Detection has been selected by Finnish airport operator, Finavia Corporation, to support the transition to Standard 3 at Helsinki Airport with approved hold baggage screening systems. Included in the contract are eight high-speed, HI-SCAN 10080 XCT scanners, which combine high resolution X-ray technology, computed tomography (CT) and advanced detection algorithms to increase both security and operational efficiency significantly. Security, speed and efficiency are critical to the extensive development programme underway at the airport, which will allow the airport to serve 30 million passengers annually and increase baggage handling capacity by 50%. “Any financial investment in upgrading security equipment has to be balanced against operational improvement, particularly when part of a major expansion. Airports need assurance that efficiencies will be gained and systems can be further updated as necessary to detect evolving explosive threats and handle ever higher volumes,” comme

Norsk Titanium Continues to Grow in the State of New York18.7.2018 07:00Pressemelding

Norsk Titanium (Norsk), the world’s first FAA-approved supplier of aerospace-grade, additive manufactured, structural titanium components, announced another major milestone in qualified production. Norsk’s Plattsburgh Development and Qualification Center (PDQC) site was officially added to the Spirit AeroSystems Approved Suppliers List (ASL) in anticipation of the start of qualified production later this year. Partnered with the recent announcements of PDQC being added to the Boeing’s Qualified Producer’s List (QPL) list and its certification under AS9100D, this new qualification is key to furthering the availability of Norsk’s disruptive technology in the aerospace market. Spirit AeroSystems is the world’s largest independent aerostructures manufacturer. “These significant achievements have been made possible by the foresight and commitment made to Norsk by the State of New York and Empire State Development. We are extremely proud of our PDQC quality and operations teams and appreciat

The Best User Interface in Mobile and Web Tracking Just got Better18.7.2018 06:00Pressemelding

ThriveTracker, a leading web and mobile tracker for media buyers and performance marketers, today announced the general availability of its latest release featuring an all-new user interface (UI). Inspired by feedback from customers and partners, ThriveTracker designed the new UI to accelerate user adoption, improve usability and increase productivity. ThriveTracker focused on the user experience for all users regardless of device, (Desktop, Mobile, etc.), making it more intuitive and accessible. Improved navigation provides simplified access to frequently used functions in the platform, increases customer awareness of more advanced functionality and delivers fast access to detailed content when necessary. Cleaner, simpler, modern UI Clear, consistent navigation focuses your attention on where you are and what you can do Improved layout delivers common functions intuitively Simplified views provide faster access to relevant content Mobile Friendly Mobile responsive based on device New